SCHEMBL7122707

SCHEMBL7122707

Cc1cc2cc(Nc3ccnc4cc(-c5nccs5)sc34)ccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EGFR P00533 18/20 0.61
FLT1 P17948 17/20 0.61
KDR P35968 1/20 0.54
SYK P43405 1/20 0.40
PRKCQ Q04759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129996 0.88 EGFR (0.59) EGFRFLT1KDRSYK
SCHEMBL7124381 0.88 EGFR (0.71) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7124392 0.85 EGFR (0.63) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7127588 0.85 EGFR (0.60) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7115466 0.84 FLT1 (0.74) EGFRFLT1KDRPRKCQ
SCHEMBL7671458 0.84 EGFR (0.62) EGFRFLT1KDRSYK
SCHEMBL7124425 0.84 EGFR (0.66) EGFRFLT1KDRSYKPRKCQ
SCHEMBL7664845 0.83 EGFR (0.57) EGFRFLT1KDRSYK
SCHEMBL7123656 0.83 EGFR (0.66) EGFRFLT1KDRPRKCQ
SCHEMBL7120775 0.83 EGFR (0.60) EGFRFLT1KDRSYKPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US claimed
US-20020004511-A1 Thiophene derivatives useful as anticancer agents LUZZIO MICHAEL JOSEPH (US) 2002-01-10 US claimed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP claimed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO claimed
CN-101328186-A Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER PROD INC (US) 2008-12-24 CN disclosed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
US-20020004511-A1 Thiophene derivatives useful as anticancer agents LUZZIO MICHAEL JOSEPH (US) 2002-01-10 US disclosed
CN-1280580-A Thienopyrimidine and thienopyridine derivatives as anticancer agents PFIZER PROD INC (US) 2001-01-17 CN disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020004511-A1 Thiophene derivatives useful as anticancer agents CCNA1, CCNE1, TP53 EGFR 698/4885FLT1 468/4885KDR 3201/4885
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 EGFR 2961/4885FLT1 1043/4885KDR 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.